Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

EU Clinical Trials Tracker

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12777 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Nov 2026, 03:17 UTC
2556
Shown in this register
most recently authorised
12,777
Total on CTIS
full historical archive
789
Phase III
within the shown window
Top member states
Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547
Narrow the registerReset
Phase
Phase I 566 Phase I/II 228 Phase II 721 Phase III 789 Phase IV 252
Lead sponsor
AstraZeneca AB 65 Merck Sharp & Dohme LLC 51 Pfizer Inc. 50 Assistance Publique Hopitaux De Paris 49 Novartis Pharma AG 47
Member state
Spain 1075 France 930 Germany 898 Italy 778 Poland 619 Netherlands 547 Belgium 455 Czechia 341
All 28 states

Trials in this register

566 of 2556 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
Janssen Cilag International
Neoplasms
France
21/11/2025
Phase I
Bambusa Therapeutics Inc.
Skin and Connective Tissue Diseases
Poland
21/11/2025
Phase I
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
20/11/2025
Phase I
Pharmacokinetics of NTRX-07 in fed and fasted participants
2025-523695-23-00Not applicable (trial is a pharmacokinetic study in healthy…
Neurotherapia Inc.
Nervous System Diseases
Hungary
19/11/2025
Phase I
Pfizer Inc.
Not possible to specify
Spain
19/11/2025
Phase I
Fuics Development Limited
Not possible to specify
Bulgaria
18/11/2025
Phase I
Laboratorios Cinfa S.A.
Not possible to specify
Portugal
17/11/2025
Phase I
Bionorica SE
Nutritional and Metabolic Diseases
Germany
17/11/2025
Phase I
Swedish Match North Europe AB
Behavior and Behavior Mechanisms
Sweden
17/11/2025
Phase I
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS
2025-523872-22-00Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)
Nrg Therapeutics Limited
Nervous System Diseases
Netherlands
17/11/2025
Phase I
Regeneron Pharmaceuticals Inc.
Nervous System Diseases
Netherlands, Belgium
17/11/2025
Phase I
Zealand Pharma A/S
Nutritional and Metabolic Diseases
Germany
17/11/2025
Phase I
The effect of SYX-5219 on an immune response in the skin.
2025-522217-27-00Atopic dermatitis (AD)
Sitryx Therapeutics Limited
Skin and Connective Tissue Diseases
Netherlands
14/11/2025
Phase I
Arvinas Operations Inc.
Nervous System Diseases
Netherlands
14/11/2025
Phase I
Boehringer Ingelheim International GmbH
Neoplasms
Belgium, Netherlands
14/11/2025
Phase I
Open label study to investigate patch adhesion of an Esflurbiprofen-containing patch in healthy volunteers
2025-523577-42-00Patch adhesion trial with healthy subjects, therapeutical i…
Teikoku Seiyaku Co. Ltd.
Musculoskeletal Diseases
Germany
13/11/2025
Phase I
Polpharma Biologics S.A.
Not possible to specify
Germany
13/11/2025
Phase I
A clinical study of MK-6050 in healthy people (MK-6050-001)
2025-523861-58-00Hidradenitis suppurativa
Merck Sharp & Dohme LLC
Immune System Diseases
Belgium
12/11/2025
Phase I
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers
2025-522402-21-00Advanced solid tumors (cutaneous melanoma, mucosal melanoma…
Kupando GmbH
Neoplasms
Germany
12/11/2025
Phase I
Bayer AG
Cardiovascular Diseases
Germany
12/11/2025
Phase I
Bayer AG
Cardiovascular Diseases
Germany
11/11/2025
Phase I
Laboratorios Leon Farma S.A.
Not possible to specify
Portugal
10/11/2025
Phase I
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
07/11/2025
Phase I
A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants
2025-522320-27-00Not applicable - healthy volunteer trial
Viatris Innovation GmbH
Not possible to specify
Netherlands
07/11/2025
Phase I
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
05/11/2025
Phase I
Laboratorios Leon Farma S.A.
Not possible to specify
Portugal
04/11/2025
Phase I
Hennig Arzneimittel GmbH & Co. KG
Not possible to specify
Portugal
04/11/2025
Phase I
AstraZeneca AB
Cardiovascular Diseases
Netherlands
03/11/2025
Phase I
Comparison of Prefilled syringe and Autoinjector presentations of FYB202
2025-522422-13-00Chronic inflammatory diseases
Fresenius Kabi SwissBioSim GmbH
Immune System Diseases
Poland
03/11/2025
Phase I
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
2025-522930-29-00Incomplete Response - Major Depressive Disorder (IR-MDD)
Otsuka Pharmaceutical Development & Commercialization Inc.
Mental Disorders
Netherlands
31/10/2025
Phase I
Climb Bio Inc.
Immune System Diseases
Romania, Bulgaria, Greece, Spain
31/10/2025
Phase I
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
2024-516625-31-00Advanced Solid Tumor
Daiichi Sankyo Inc.
Neoplasms
Spain, France
30/10/2025
Phase I
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase I
Sun Pharmaceutical Industries Limited
Mental Disorders
Romania
27/10/2025
Phase I
Sun Pharmaceutical Industries Limited
Mental Disorders
Romania
27/10/2025
Phase I
Sun Pharmaceutical Industries Inc.
Immune System Diseases
Romania
27/10/2025
Phase I
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase I
Vertero Therapeutics Inc.
Nervous System Diseases
Netherlands
27/10/2025
Phase I
Chong Kun Dang Pharmaceutical Corp.
Immune System Diseases
Poland
26/10/2025
Phase I
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes
2024-519382-22-00Healthy Participants and Participants with type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
24/10/2025
Phase I
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands
22/10/2025
Phase I
Dompe' Farmaceutici S.p.A.
Pathological Conditions, Signs and Symptoms
Netherlands
17/10/2025
Phase I
Eli Lilly & Co.
Digestive System Diseases
Slovakia, Hungary
17/10/2025
Phase I
Gan & Lee Pharmaceuticals USA Corp.
Hormonal diseases
Germany
15/10/2025
Phase I
A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors
2025-521535-36-00Locally advanced, metastatic NSCLC, CRC, or HNSCC that has …
Janssen Cilag International
Neoplasms
Spain
15/10/2025
Phase I
Amsterdam UMC Stichting
Neoplasms
Netherlands
15/10/2025
Phase I
Laboratorios Normon S.A.
Not possible to specify
Spain
15/10/2025
Phase I
ProQR Therapeutics VIII B.V.
Nutritional and Metabolic Diseases
Netherlands
14/10/2025
Phase I
Region Midtjylland
Neoplasms
Denmark
14/10/2025
Phase I
Adamed Pharma S.A.
Mental Disorders
Czechia
13/10/2025
Phase I
Pfizer Inc.
Cardiovascular Diseases
Belgium
10/10/2025
Phase I
Bioprojet Pharma
Nervous System Diseases
Belgium
10/10/2025
Phase I
Allysta Pharmaceuticals Inc.
Nutritional and Metabolic Diseases
Bulgaria
10/10/2025
Phase I
ENYO Pharma
Digestive System Diseases
France
09/10/2025
Phase I
Bacoba AG
Immune System Diseases
Germany
09/10/2025
Phase I
Sitryx Therapeutics Limited
Skin and Connective Tissue Diseases
Germany, Bulgaria, Ireland, Denmark
09/10/2025
Phase I
Laboratorios Alter S.A.
Mental Disorders
Spain
09/10/2025
Phase I
Laboratorios Normon S.A.
Not possible to specify
Spain
08/10/2025
Phase I
Esperante Development B.V.
Otorhinolaryngologic Diseases
Czechia
08/10/2025
Phase I
Merck Sharp & Dohme LLC
Nutritional and Metabolic Diseases
Belgium
08/10/2025
Phase I
PharOS Pharmaceutical Oriented Servises Ltd., CCDRD Cooperative Clinical Drug Research and Development AG
Not possible to specify
Bulgaria
08/10/2025
Phase I
Triveni Bio Inc.
Skin and Connective Tissue Diseases
Netherlands
07/10/2025
Phase I
Regeneron Pharmaceuticals Inc.
Immune System Diseases
Spain, France, Germany
07/10/2025
Phase I
International Vaccine Institute
Bacterial Infections and Mycoses
Sweden
06/10/2025
Phase I
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00Axial spondyloarthritis
Grey Wolf Therapeutics Limited
Hemic and Lymphatic Diseases
Belgium, Germany, Netherlands, Spain, Poland
06/10/2025
Rows per page Showing 501–566 of 566
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 November 2026. https://priyalifescience.com/clinical-trials-europe?page=2

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,777 trial records at the last sync on 06 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 566 of those trials that match the filters currently applied.

How many clinical trials does CTIS hold?

CTIS held 12,777 trial records at the last sync. Of the 2,556 most recently authorised trials shown in this register, 789 are Phase III, and 566 match the filters currently applied. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by member state

Spain (1075) France (930) Germany (898) Italy (778) Poland (619) Netherlands (547) Belgium (455) Czechia (341) Denmark (319) Hungary (254) Greece (237) Austria (219) Romania (219) Bulgaria (218) Sweden (200)
→

Browse trials by condition

Advanced solid tumors (23) Atopic Dermatitis (19) Non-Small Cell Lung Cancer (15) Obesity (14) Parkinson’s disease (14) Multiple sclerosis (13) Rheumatoid arthritis (13) Breast Cancer (11) Ulcerative colitis (11) Prostate Cancer (10)
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.